The marketing authorisation for Revasc has been withdrawn at the request of the marketing-authorisation holder.
Revasc : EPAR - Summary for the public (PDF/149.28 KB)
First published: 16/07/2007
Last updated: 16/07/2007
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Canyon Pharmaceuticals Ltd.
|Date of issue of marketing authorisation valid throughout the European Union||
Canyon Pharmaceuticals Limited
52-54 Gracechurch Street
23/01/2012 Revasc - EMEA/H/C/000104 - IAIN/0031/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.